12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Impracor: Phase III start

This quarter, Imprimis will begin a double-blind, placebo-controlled, U.S. Phase III trial to evaluate Impracor for 14 days in about 350 patients. Imprimis is developing Impracor under section 505(b)(2) of...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >